Imugene says Azer-cel could be best-in-class Allogeneic CAR T

–News Direct–

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive soon after announcing the company has passed a major milestone for its Azer-cel therapy treatment with the dosing of the first patient for its Phase 1b Allogeneic CAR T Clinical Trial. It follows a Phase 1a trial that included 84 patients across leading US healthcare centres and offered strong safety and efficacy signals according to IMU. The second part of this Phase 1 trial involves the study of Azer-cel in an ongoing, multi-centre clinical trial in patients with non-Hodgkins lymphoma blood cancer, and serves as a precursor to Phase 2 registrational (subject to FDA approval) in 2024.

It is a great credit to our team that the Phase 1b study has been initiated and the first patient dosed, in under three months since acquiring the technology, Chong said.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Imugene Ltd

comtex tracking


Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Knox Market Research journalist was involved in the writing and production of this article.